About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- 12 people with Barth syndrome randomised; 10 continued into the open-label part
- Sample size
- 12
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Very small, crossover design in an ultra-rare disease. One author is employed by Stealth BioTherapeutics, the developer. The open-label part has no control group. Abstract read via Europe PMC; full text not read.
Cited in
Barth syndrome crossover trial, primary endpoints not met
Elamipretide · Research finding
Preliminary
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.